MediciNova (MNOV) Stock Price, News & Analysis

Company Overview

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Key Stats

• Today's Range: $1.25 to $1.31
• 50-Day Range: $1.26 to $1.59
• 52-Week Range: $1.12 to $2.55
• Volume: 68,347 shs
• Average Volume: 36,369 shs
• Market Capitalization: $61.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Strong Buy

MediciNova Stock Analysis - MarketRank™

MediciNova scored higher than 37% of companies evaluated by MarketBeat, and ranked 690th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

MediciNova has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MediciNova has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for MediciNova are expected to remain at ($0.24) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of MediciNova is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MediciNova is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MediciNova has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.35% of the float of MediciNova has been sold short.

Short Interest Ratio / Days to Cover

MediciNova has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.

Change versus previous month

Short interest in MediciNova has recently decreased by 2.16%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MediciNova does not currently pay a dividend.

Dividend Growth

MediciNova does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.35% of the float of MediciNova has been sold short.

Short Interest Ratio / Days to Cover

MediciNova has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.

Change versus previous month

Short interest in MediciNova has recently decreased by 2.16%, indicating that investor sentiment is improving.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MediciNova insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.60% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 9.90% of the stock of MediciNova is held by institutions.

MNOV Stock Analysis - Frequently Asked Questions

How have MNOV shares performed this year?

MediciNova's stock was trading at $2.10 on January 1st, 2025. Since then, MNOV shares have decreased by 40.0% and is now trading at $1.26.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.08.

How do I buy shares of MediciNova?

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MediciNova own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MediciNova investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Inuvo (INUV).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MNOV
• CIK: 1226616
• Web: medicinova.com
• Phone: (858) 373-1500
• Fax: 858-404-0048
• Employees: 10
• Year Founded: 2000

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +455.6%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.04 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.77%
• Return on Assets: -19.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.66
• Quick Ratio: 17.66

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 61.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.07 per share
• Price / Book: 1.18

Miscellaneous

• Outstanding Shares: 49,050,000
• Free Float: 42,376,000
• Market Cap: $61.80 million
• Optionable: Optionable
• Beta: 0.40